|
Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Exclusive Content
Aehr Test Systems: Small AI Stock Sees Record AI Hyperscaler OrderAuthored by Leo Miller. Posted: 4/22/2026. 
Key Points
- Aehr Test Systems just keeps winning AI orders, and shares are soaring
- The company's latest win is its largest to date, coming from a repeat hyperscaler customer
- Aehr is raising cash to fund growth, generating $60 million in gross proceeds from an equity issuance
- Special Report: Elon Musk’s $1 Quadrillion AI IPO
The small semiconductor stock Aehr Test Systems (NASDAQ: AEHR) is drawing increasing interest from customers and investors in 2026. Year to date, Aehr has soared more than 350%, making it one of the best-performing stocks in the U.S. market. Behind Aehr’s surge is accelerating demand from artificial intelligence (AI) customers. Aehr’s two primary products are its Sonoma and FOX‑XP systems, which stress-test chips and wafers under extreme conditions to help prevent faulty devices from entering data centers. With companies spending billions on AI infrastructure, Aehr’s test systems play a role in protecting those investments.
Most people overcomplicate trading, chasing ten indicators, 20-year-old gurus, and seventeen secret systems, and somehow end up more confused than when they started. I found one setup—just one—that kept showing up every morning at the same time, same pattern, same opportunity, and it worked often enough that I stopped trying to reinvent the wheel. By 10 AM, I'm usually done for the day, no drama, no 14-hour trading sessions, just one repeatable moment that anyone with a laptop can learn to spot. Get your free Opening Bell Breakouts trade guide here
After a string of orders, Aehr has now announced its largest order to date. Hyperscaler Re-Ups on Sonoma With Record $41 Million OrderIn mid-April, Aehr said it received a record $41 million production order from its lead hyperscale customer. According to the company, “The order is the largest in Aehr’s history.” The order is for the firm’s Sonoma systems, which test chips after packaging; FOX‑XP is used earlier at the wafer level. The customer will use Sonoma to test current-generation AI processor application-specific integrated circuits (ASICs), often called “custom silicon” or XPUs. Companies such as Broadcom (NASDAQ: AVGO) and Marvell Technology (NASDAQ: MRVL) co-develop these chips with massive hyperscalers like Meta Platforms (NASDAQ: META) or Amazon.com (NASDAQ: AMZN). Mentioning these names provides context for investors and is not intended to suggest the identity of Aehr’s customer. This is another follow-on order for the customer’s current-generation chip testing needs. Aehr made similar announcements in July 2025 and August 2025, though the company did not disclose the sizes of those orders, suggesting they were smaller. Repeat orders indicate the customer values Sonoma’s capabilities, and the latest, much larger purchase suggests a significant ramp in their commitment. This reinforces Aehr’s competitive position in the AI infrastructure supply chain. Aehr’s Orders Shoot to Over $90 Million, Far Above Previous EstimatesAehr has now exceeded its own order forecasts. The company had expected H2 FY2026 orders of $60 million to $80 million. With roughly five weeks left in its fiscal year—its reporting calendar is offset from the calendar year—H2 bookings have climbed above $92 million. That total is roughly 31% higher than the midpoint of prior guidance, and continued order announcements could push the figure even higher. Aehr is also working with this customer on a next‑generation AI processor ASIC and received an initial order to supply Sonoma systems for that device in February. The company expects the next‑generation chip to enter production sometime in calendar 2026. As Aehr noted, “As these next-generation devices move into volume production, we see the potential for further substantial increases in demand for Sonoma systems and consumables in our next fiscal year.” Given the repeat orders for the current-generation device, similar demand for the next generation would not be surprising. Aehr is attracting interest across a range of data-center technologies, including the hyperscaler mentioned above and a silicon photonics customer. Silicon photonics is a networking technology that allows data-center components to communicate more efficiently. The company also says it is engaging with potential customers in flash memory and high‑bandwidth memory. Flash memory examples include firms like SanDisk (NASDAQ: SNDK), while Micron Technology (NASDAQ: MU) is a notable name in high‑bandwidth memory. These mentions are for investor reference and do not imply specific engagements. Aehr Issues Shares, Adding Tens of Millions to Its Balance SheetRecently, Aehr issued a significant number of shares, raising about $60 million in gross proceeds. Although dilutive to existing shareholders, the capital substantially bolsters Aehr’s cash position; the company reported roughly $36.9 million in cash and equivalents at the end of its last quarter. For a company with demand accelerating, the raise is largely positive. It suggests Aehr is funding capacity expansion to meet current orders and to position itself for future demand. |
Post a Comment
Post a Comment